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Abstract Diabetes mellitus is characterized by chronic in-
flammation and increased risk of infections, particularly of
tissues exposed to the external environment. However, the
causal molecular mechanisms that affect immune cells and
their functions in diabetes are unclear. Here we show, by
transcript and protein analyses, signatures of glucose-induced
tissue damage, chronic inflammation, oxidative stress, and
dysregulated expression of multiple inflammation- and
immunity-related molecules in diabetic kidneys compared
with non-diabetic controls. Abnormal signaling involving
cytokines, G-protein coupled receptors, protein kinase C iso-
forms, mitogen-activated protein kinases, nuclear factor-κB
(NFκB), and Toll-like receptors (TLR) were evident. These
were accompanied by overexpression of negative regulators of
NFκB, TLR, and other proinflammatory pathways, e.g., A20,
SOCS1, IRAK-M, IκBα, Triad3A, Tollip, SIGIRR, and ST2L.
Anti-inflammatory and immunomodulatory molecules, e.g.,
IL-10, IL-4, and TSLP that favor TH2 responses were strongly
induced. These molecular indicators of immune dysfunction
led us to detect the cryptic presence of bacteria and human
cytomegalovirus in more than one third of kidneys of diabetic
subjects but none in non-diabetic kidneys. Similar signaling
abnormalities could be induced in primary human renal tubular
epithelial (but not mesangial) cell cultures exposed to high
glucose, proinflammatory cytokines and methylglyoxal, and
were reversed by combined pharmacological treatment with an
antioxidant and a PKC inhibitor. Our results suggest that
diabetes impairs epithelial immunity as a consequence of
chronic and inappropriate activation of counter-regulatory im-
mune responses, which are otherwise physiological protective
mechanisms against inflammation. The immune abnormalities
and cryptic renal infections described here may contribute to
progression of diabetic nephropathy.
Keywords Diabetes mellitus . Inflammation . Immune
homeostasis . Renal epithelium . Bacterial infection .
Cytomegalovirus
Introduction
Many studies have shown infection to be a major cause of
death among diabetics [1–5]. A prospective 15-year study
revealed a 41-fold higher risk of death from infections
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compared with the referent population [5]. Host-specific
factors have been implicated as contributing to abnormali-
ties of innate and adaptive immunity [6–9]. Abnormalities
of innate immunity mediated by leukocytes, macrophages,
natural killer, and dendritic cells have been observed in
diabetes [7–9]. Disordered cell-mediated immunity in dia-
betes is reflected in reduced leukocyte adherence, chemo-
taxis and phagocytosis, impaired oxidative burst and
intracellular bactericidal activities, and diminished produc-
tion of antimicrobial cytokines [7, 10–13]. Diabetes also
impairs adaptive immunity via the cell-mediated arm [14,
15] and humoral immunity [7]. Despite evidence of diverse
alterations of immune function in vitro, their relevance to
the risk of infections among diabetic patients in vivo is
controversial [16–18]. Nonetheless, indubitable evidence
correlates good glycemic control with improved immune
function and lower infection rates [1, 14, 19].
Here, we describe mechanisms that impair epithelial im-
munity in kidneys in human diabetes. We hypothesized that
cross-talk between immune cells and resident tissue cells
could be key in maintaining tissue immune homeostasis and
mounting appropriate immune responses. Epithelial cells
can detect microbial infections and are indispensable in
“coaching” the behavior of immune cells [20, 21].
We chose kidney as a model tissue because urinary tract
infection is common among diabetics and diabetic end-stage
renal disease remains a major clinical challenge. We analyzed
histologically normal, fresh human kidney tissues procured
from non-diabetic and diabetic subjects who had clinically
normal renal function. The use of non-nephropathic kidney
tissues allowed us to document molecular perturbations that
precede clinical complications of chronic diabetes, uncon-
founded by renal parenchymal disease. As diabetes-
associated target tissue injury occurs before loss of clinical
function [22], documenting pre-clinical molecular dysregula-
tions may enable more effective approaches to prevent and
treat diabetes-induced renal dysfunction.
Our results suggest that diabetes and hyperglycemia per
se impair renal epithelial immunity as a consequence of
inappropriately activated negative counter-regulatory
responses, which are physiological protective mechanisms
against chronic inflammation. The immune abnormalities
and cryptic bacterial and viral infections we discovered in




DNA, RNA, and protein were extracted from tumor-distant
tissues of kidneys surgically removed for renal carcinoma.
All patients received no anticancer treatment before ne-
phrectomy. Bacteria and human CMV were detected in
DNA from fresh and formalin-fixed paraffin-embedded
(FFPE) kidney tissues. Table S1 in the Electronic supple-
mentary material (ESM) summarizes the clinical profiles of
all patients in this study which was approved by the Sing-
Health Institutional Review Board.
DNA, RNA, and protein isolation from human kidney
Kidney tissues, flash frozen in liquid nitrogen, were verified
to be cancer free and to have no diagnostic features specific
for diabetic nephropathy by histological examination. None
of the patients had clinical evidence of urinary infection or
significant albuminuria. Frozen tissues were diced in All-
Protect tissue reagent (Qiagen), immersed in tissue lysis
buffer for DNA, RNA, or protein isolation and disrupted
in Tissuelyser LT (Qiagen). DNA, RNA, or proteins were
purified from tissue lysates using the appropriate kits and
protocols (Qiagen). Membrane proteins were isolated with
Q proteome cell compartment kit (Qiagen). On-column
digestion of DNA was performed during RNA isolation
using RNase-free DNase (Qiagen).
Antibodies and reagents
Suppliers of antibodies, reagents, and kits were: antibodies
against IRAK isoforms, MyD88, RIG-1, A20, SOCS1, NIK
and IκBα, NFκB p65, p38 MAPK, JNK, Akt, and their
phosphorylated proteins (Cell Signaling Technology); anti-
bodies against actin, Triad3A, TRAF6, protein kinase C
(PKC)-βII, Sod2, Nox4, and goat IgG-HRP (Santa Cruz
Biotechnology); antibodies against TLR4 and phosphorylat-
ed PKC-βII (Abcam); clinical grade CellGro® GMP TNF-
α, IL-6, and IL-1β (CellGenix GmbH); methylglyoxal,
lipopolysaccharide (LPS) from Escherichia coli 055:B5,
lipoteichoic acid from Staphylococcus aureus, diphenyle-
neiodonium chloride (DPI), and Gö6983 (Sigma-Aldrich);
poly(I:C) (Pharmacia Biotech); iScript™ cDNA synthesis
kit (Bio-Rad); protease inhibitor cocktail (Roche), and west-
ern blot reagents (Amersham ECL™ blocking agent, Ad-
vance western blotting detection kit, and mouse- and rabbit
IgG-HRP antibodies) were from GE Healthcare.
Cell culture
Clonetics® human primary renal tubular epithelial cells
(RPTEC) and mesangial cells (NHMC), purchased from
Lonza BioSciences, were cultured in REGM™ Renal Epi-
thelial Cell Growth Medium and NHMC in MsGM™
Mesangial Cell Growth Medium, respectively. Cells were
subcultured with ReagentPack™ Subculture Reagents. For
all experiments, 2.5×104 RPTEC/well or 3.5×104 NHMC/
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well were seeded in a six-well plate at 37 °C, 5 % CO2 and
cultured for 3 days before experiments commenced. Cells
having the same experimental treatment were lysed directly
in situ and pooled for total RNA and protein isolation. Endo-
toxin levels of culture media were assayed with an endotoxin
detection kit (Lonza Biosciences).
Western blot analysis
Protein concentrations of fresh frozen kidney tissue lysates
(n08 each for diabetic and non-diabetic samples) and pri-
mary renal cell lysates were quantitated using the bicincho-
ninic acid method (Thermo Scientific). Lysates were
resolved on SDS-PAGE and transferred onto PVDF mem-
branes using Trans-blot Semidry (Bio-Rad). Immunoblot-
ting was performed using individual primary antibodies,
goat-, mouse- or rabbit IgG-HRP secondary antibodies,
proprietary blocking, and detection reagents stated above.
Quantitative RT-PCR
Transcript levels of 90 genes in fresh frozen human kidney
tissues and primary renal cell samples were assayed with
custom 96-gene RT2 Profiler™ PCR arrays (SABiosciences,
Qiagen). Six diabetic kidneys positive for both bacteria and
CMV were compared with six non-diabetic kidneys that
were negative for both. Briefly, first-strand cDNA was gen-
erated with RT2 First Strand Kit. Quantitative PCR was
performed using RT2 quantitative polymerase chain reaction
(qPCR) master mix and proprietary primer pairs for each of
the 90 genes (Bio-Rad CX96 thermal cycler). The transcript
level of each gene was normalized with reference to
GAPDH, ACTB, and RPL13A. Criteria for efficiency of
reverse transcription and PCR, and genomic DNA contam-
ination met the standards specified by the supplier.
Quantitation of cytokines
Levels of 20 cytokines in fresh frozen kidney tissue lysates
(n09 each for diabetic and non-diabetic samples) and pri-
mary renal cell lysates were quantitated by a sandwich-
ELISA method using a custom Quantibody® Human Cyto-
kine Array (RayBiotech, Inc.). Fluorescence signals ac-
quired with Axon GenePix (Molecular Devices) were
analyzed with RayBio® Q Analyzer (RayBiotech, Inc.)
Detection of microbial DNA in kidneys
FFPE kidney tissues of patients of known diabetes status were
sectioned for DNA isolation using QIAamp DNAFFPE tissue
kit (Qiagen). Sections from the surface of tissue blocks were
not used. Quantitative PCR using GoTaq® qPCR master mix
(Promega) and primer pairs that amplify a 1.3-kb DNA
sequence specific to bacteria [23] was performed on 50 ng
DNA isolated from FFPE or fresh frozen kidney tissues. The
amount of bacterial DNA in the sample was determined from
a standard curve generated from unrelated human DNA
spiked with known amounts of bacterial DNA isolated from
Lactobacillus sp. and E. coli. CMV DNAwas detected using
Artus® CMVRG PCR kit (Qiagen). Table S1 in the ESM lists
the source of tissues for microbial DNA analysis.
Data analysis
All data were expressed as mean±SEM. Statistical analyses
(GraphPad Prism®) between groups were performed with
parametric, unpaired Student’s t test. Welch’s correction was
included if the variance was unequal. Linear correlation was
performed to establish association.
All genes and proteins studied are listed in functional
groups in Table S2 in the ESM.
Results
Kidney tissues express molecular signatures of diabetes
Fresh frozen tumor-free kidney tissues were obtained from
nine type 2 diabetic and nine non-diabetic subjects of compa-
rable age, body mass index, and gender distribution (Table S1
in the ESM). The diabetes status of each patient was identified
by the most recent glycated hemoglobin (HbA1c) level and/or
a record of current treatment for diabetes. All patients had
unimpaired renal function (serum creatinine, ≤110 μM
(males) or ≤85 μM (females)).
By quantitative RT-PCR, immunoblotting, and antibody
arrays, diabetic renal tissues showed increased activity of
the polyol and hexosamine pathways, PKC signaling, and
increased expression of AGER compared with non-diabetic
controls (Fig. 1) Other known abnormalities detected were
increased expression of NFAT5, EGR1, SPP1, INSR, and
AGTR1. Increased transcription of extracellular matrix pro-
tein genes, BGN, FN1, COL1A1, and THBS1 coupled with
decreased expression of E-cadherin in diabetic kidneys was
consistent with epithelial–mesenchymal transition which
has been implicated in the pathogenesis of diabetic
nephropathy [24].
These data supported the use of tumor-free kidney tissues
for studying tissue effects of diabetes unconfounded by
renal parenchymal disease. Transcript levels of AKR1B1,
SORD, AGER, TGFB1, PAI1, PRKCB, EDN1, VEGFA,
BGN, FN1, COL1A1, THBS1, EGR1, and NFAT5, all impli-
cated in diabetes complications, correlated significantly with
HbA1c levels of diabetic subjects (Fig. S1 in the ESM),
confirming molecular effects of hyperglycemia on renal
tissue even before functional impairment.
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Non-nephropathic kidneys of diabetic patients are inflamed
Chronic inflammation is a hallmark of diabetes [25]. To
investigate effects of inflammation on immunity in diabetes,
we assayed adhesion molecules, cytokines, chemokines, and
their receptors in renal tissues. Diabetic kidneys had signif-
icantly higher levels of proinflammatory molecules (MCP-
1, Rantes, TNF-α, GRO, and IL-6) compared with controls
(Fig. 2a). Transcript levels of IL8, IL18, SELE, ICAM1,
CEBPB, and PDGFRA were all higher in diabetic kidneys
(Fig. 2b).
Inflammation in diabetic kidneys is associated
with increased GPCR and MAP kinase activities,
and oxidative stress
Signaling pathways associated with chronic inflammation
were observed in diabetic kidneys, evidenced by increased
protein levels and phosphorylation of PKC-βII (Fig. 2c) and
NFκB (p65), increased expression of PRKCA, PRKCB, and
PRKCQ (Fig. 1b) and increased phosphorylation of
MAPK14 (p38 MAPK) and c-Jun N-terminal kinase
(JNK). Concomitantly, GPCR signaling molecules that reg-
ulate these pathways were induced. GNAQ and PLCB1 were
upregulated, as were activators of NFκB (BCL10 and
PTK2B (PYK2)), p38 MAPK (MAP3K5 or ASK1), and
JNK (PTK2B) (Fig. 2b). Akt activation in diabetic kidneys
was noteworthy because it is known to activate NFκB, JNK,
and extracellular signal-regulated kinase (Fig. 2c).
Increased oxidative stress activating NFκB has been im-
plicated in diabetes complications [26]. Diabetic kidneys
had increased transcript and membrane-bound protein levels
of Nox4, the renal-specific generator of cytosolic reactive
oxygen species (ROS) and reduced expression of SOD2,
UCP2, GPX3, NQO1, and CAT (Fig. 2b, c). Impaired anti-
oxidative capacity was implied by decreased expression of
Fig. 1 Tumor-free tissues from nephrectomized diabetic kidneys show
molecular features of diabetes mellitus. a Protein lysates of histopath-
ologically qualified tumor-free renal cortical tissues from diabetic and
non-diabetic patients were assayed for the proteins indicated using a
multiplex ELISA-based array (RayBiotech Inc.). The specific protein
concentration in each kidney lysate was assayed in quadruplicate and
quantitated from a standard curve, built into the multiplexed assay,
using markers of known concentrations. All diabetic samples (n09)
were positive for HCMV, bacteria or both. All non-diabetic samples
(n09) were negative for HCMV and bacteria. b Tumor-free renal
cortical tissues from diabetic and non-diabetic patients were homoge-
nized for DNA, RNA, and protein isolation. RNA integrity and quality
were verified (Bioanalyzer, Agilent) before qPCR assay. Shown are the
results of qPCR array (SABiosciences, Qiagen) that assayed for 21
gene transcript levels using proprietary primers. The transcript level of
each gene in each kidney sample was inter-ranked and presented as a
pre-assigned color dendogram (D diabetic patients 1–6, ND non-
diabetic patients 1–6). Each diabetic sample had evidence of both
HCMV and bacterial infection while all non-diabetic samples were
negative for both HCMV and bacteria. Yellow-lined borders highlight
the only downregulated gene in each category. Fold change (D/ND) for
each gene was calculated using the average transcript levels of all
subjects in a group, which is accompanied by standard deviation.
(SD)*. P≤0.05, comparison between diabetic and non-diabetic is
significant.
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NFE2L2, HMOX1, GSS, MSRA, and TXNRD1 (Fig. 2b). In
aggregate, these results point to increased oxidative stress in
diabetic kidneys.
The paradox of heightened inflammation and impaired
immunity in diabetes
The foregoing changes in diabetic kidneys raise a paradox.
How do heightened inflammatory responses in diabetes
coexist with increased susceptibility to infections, since the
former should, in theory, combat microbial invasions more
effectively? We hypothesized that the dual effects of TGF-β
overexpression could help to resolve this paradox (Fig. 1).
TGF-β potentiates inflammation and induces renal fibrosis
but is also important in regulating immune homeostasis
[27]. Assaying other immunomodulatory molecules, we
showed significant upregulation in diabetic kidneys of IL-4,
TSLP, IL-1RN, IL-10, and IL-10Rb, which have anti-
inflammatory and immunosuppressive actions (Fig. 3a). Con-
versely, IL1-R1 and IL6-R1 were downregulated in diabetic
kidneys. Expression of TNFRI, the major TNF-α receptor,
was not significantly altered. Antibacterial chemokines, GCP-
2 (CXCL6), and MIP-3α (CCL20), were reduced in diabetic
kidneys (Fig. 3a).
Next, we examined negative regulators of inflammatory
signaling. In diabetic kidneys, suppression of Toll-like re-
ceptor (TLR) signaling was associated with overexpression
of its negative regulators (Fig. 3b, c). The level of A20 was
higher in diabetic kidneys and correlated with lower tran-
script and protein levels of TRAF6. Negative regulators of
proinflammatory surface receptors were also overexpressed
in diabetic kidneys. Triad3A (RNF216) was significantly
higher in diabetes and may have contributed to reduced
levels of TLR4 protein (Fig. 3c). Similarly, IRAK-M was
overexpressed while IRAK4 protein was repressed in dia-
betic kidneys. Upregulation of transcripts of IL1RL1 (ST2L)
and SIGIRR of the TIR superfamily, may also modulate
TLR signaling in diabetic tissues (Fig. 3b). Upregulation
of IL1RL1 and SIGIRR was consistent with lower protein
levels of MyD88, TLR4, IRAK4 and TRAF6 in diabetic
Fig. 2 Diabetic kidneys with clinically normal renal function are
inflamed. a Significantly higher concentrations of common proinflam-
matory cytokines were detected in fresh frozen kidneys of diabetic (n0
9) than in non-diabetic (n09) subjects using a custom Quantibody®
Human Cytokine Array (RayBiotech, Inc.) b Transcript levels of genes
implicated in inflammation (6 genes), G protein-coupled receptor
(GPCR) signaling (5 genes), and antioxidant pathway (12 genes) were
analyzed by qPCR array. Transcripts for genes implicated in inflam-
matory and GPCR pathways were upregulated in diabetic kidneys
while transcripts encoding antioxidant enzymes were downregulated
but Nox4, a superior generator, was upregulated. The fold change was
calculated from expression levels in fresh frozen kidney tissues of six
diabetic subjects (each positive for both HCMV and bacteria) com-
pared with an equal number of non-diabetic subjects (negative for both
HCMV and bacteria). c Kidney lysates and organelle-specific proteins
of diabetic and non-diabetic subjects (n09 each) were assayed by
western blot analysis with the indicated antibodies. All nine diabetic
samples were positive for HCMV, bacteria or both. All nine non-
diabetic samples were negative for both HCMV and bacteria. The P
values compare the expression levels of diabetic and non-diabetic
subjects and were calculated based on actin-normalized densitometry
values of each group. Western blot experiments for each antibody were
repeated at least thrice. Representative blots for each antibody are
shown
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kidneys (Fig. 3c). Overexpression of TOLLIP in diabetes
was yet another possible mechanism for inhibition of TLR2-
and TLR4-mediated NFκB activation.
SOCS1, a negative regulator of several inflammatory path-
ways, was more highly expressed in diabetic kidneys (Fig. 3b,
c). PTEN transcription was increased. Other known negative
regulators of proinflammatory pathways upregulated in dia-
betic kidneys included ARRB1, PIN1 and UBA1 (Fig. 3b).
Taken together, our results showed that multiple counter-
regulatory mechanisms against heightened inflammation were
excessively activated in diabetic kidneys, causing loss of im-
munological homeostasis that could impair immune defenses.
Increased expression of negative regulators is associated
with impaired immunity and cryptic microbial infections
in diabetic kidneys
Transcription of genes encoding antimicrobial peptides
(LEAP2, PIGR, and LTF) and complement factors (C2,
C3, C4A, and C5), were all repressed in diabetic kidneys,
except for DEFB1, which is known to be glucose-induced
(Fig. 4a). Adaptive immunity was also impaired. Genes
encoding antigen-presenting proteins, TAP1, TAP2, TAPBP,
HLA-A, and HLA-E, were repressed in diabetic kidneys.
High expression of HLA-DPA1 and HLA-DQA1 in diabetic
Fig. 3 Upregulation of several negative regulators of inflammation
is associated with impaired Toll-like receptor signaling in diabetic
kidneys. a Significantly higher expression of immunomodulatory
and anti-inflammatory cytokines and signaling molecules (TSLP,
IL-10, IL-10Rb, IL-4, and IL-1RN) but suppressed expression of
antimicrobial cytokines (GCP-2 and MIP-3α) and cytokine recep-
tors (IL1-R1, IL-6R) in fresh frozen diabetic kidneys (n09 (black
squares); cf. non-diabetic kidneys, n09 (triangles)) using a cus-
tom Quantibody® Human Cytokine Array (RayBiotech, Inc.). b
Diabetic kidneys showed significant upregulation of all negative
regulators tested (14 genes) but downregulation of 8 of 14 genes
involved in TLR signaling. Fold change for each gene represents
the average transcript levels of fresh frozen diabetic kidneys
compared with non-diabetic kidneys (n06 each). Six diabetic
subjects (each positive for both HCMV and bacteria) were com-
pared with an equal number of non-diabetic subjects (negative for
both HCMV and bacteria). c Western blot analysis of negative
regulators of inflammation (A20, Triad3A, IRAK-M, SOCS1, and
IκBα) and TLR signaling molecules (TLR4, MyD88, IRAK4,
TRAF6, and NIK) confirmed their higher and lower expression,
respectively, in fresh frozen diabetic kidneys. The P value for
each paired comparison was calculated from actin-normalized
densitometry values of diabetic (n08) and non-diabetic (n08)
kidneys. All eight diabetic samples were positive for HCMV,
bacteria or both. All eight non-diabetic samples were negative
for both HCMV and bacteria. Western blot experiments for each
antibody were repeated at least thrice. Representative blots for
each antibody are shown
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kidneys suggested internalized microorganisms in renal
cells. To investigate clinically silent infections in diabetic
kidneys, assay for HCMV DNA using a clinical diagnostic
kit revealed the cryptic presence of HCMV DNA in six of
nine fresh frozen and three of seven FFPE samples, giving a
total positivity of 9 of 16 (56 %) in diabetic kidneys
(Fig. 4b). Quantitative PCR using bacteria-specific primers
[23] showed that 13 of 19 (68 %) of diabetic kidneys and 2
of 11 (18 %) of non-diabetic kidneys had >50 pg of bacterial
DNA/50 ng total DNA. In contrast, 9 of 11 (82 %) of non-
diabetic kidneys and 5 of 5 negative controls (lymphocyte
DNA from unrelated non-diabetic subjects) had <1 pg of
bacterial DNA/50 ng total DNA. Among diabetic kidneys
tested for both HCMV and bacteria (n016), six had both
HCMV and bacterial DNA, three had HCMV DNA only,
and seven had bacterial DNA only. Consistent with the
presence of cryptic infections, cytoplasmic pathogen-
associated molecular pattern (PAMP) receptors (RIG-1,
TLR3, TLR7, HMGB1, NOD1, and NLRP3) were upregu-
lated in diabetic kidneys positive for HCMVand/or bacterial
DNA (Fig. 3b, and 4a, c). Figure 5 shows T and B lympho-
cyte infiltration in two diabetic kidneys that were positive
for HCMV and bacterial DNA.
PKC inhibition and antioxidant reverse impaired immune
responses in renal epithelial cells
To identify the resident cell type that plays a major role in
the immune responses of whole kidney, we investigated
human primary RPTEC and NHMC. RPTEC responded to
diabetes-relevant concentrations of metabolic insults (high
glucose (HG; 20 mM), methylglyoxal (MG; 10 μM), and
cytokines (TNF-α, IL-6, and IL-1β)) not only by activating
proinflammatory signaling molecules and increasing expres-
sion of proinflammatory cytokines but also by upregulating
immunoregulatory molecules (e.g., IL-4, IL-10, TGF-β, and
Fig. 4 Immune-impaired diabetic kidneys had cryptic microbial infec-
tions. a Transcript levels of genes encoding antimicrobial peptides,
serum complement factors, antigen presentation proteins (15 genes),
and cytosolic pathogen pattern recognition receptors (3 genes) were
assayed on fresh frozen kidney tissues with qPCR array. The fold
change was calculated from renal expression levels of six diabetic
subjects (each positive for both HCMV and bacteria) compared with
an equal number of non-diabetic subjects (each negative for both
HCMV and bacteria). b A clinical diagnostic kit, artus® CMV RG
PCR kit (Qiagen GmbH), was used to detect HCMV DNA in 16
diabetic (nine fresh frozen and seven FFPE) and 3 non-diabetic kidneys
(all fresh frozen). The diagnostic kit detects specific amplification of a
105-bp DNA region of the HCMV genome. Real-time PCR was
performed on Rotor-Gene™ 3000 (Roche) as instructed. Data were
analyzed with Rotor-Gene™ software. c The relative expression levels
of RIG-1 were derived from the average of actin-normalized densitom-
etry values of diabetic and non-diabetic kidneys (n08 each). All eight
diabetic samples were positive for HCMV, bacteria or both. All eight
non-diabetic samples were negative for both HCMV and bacteria.
Western blot analysis was performed at least thrice. A representative
blot is shown
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TSLP) and negative regulators of inflammation (e.g., IκBα,
IRAK-M, Triad3A, and A20) (Fig. 6). These responses were
significant after a 5-day stimulation with any single agent
(Fig. 6a, e). In contrast, although mesangial cells exposed to
the same agents showed proinflammatory responses, they
expressed very low levels of negative regulators and immu-
noregulatory proteins (Fig. 6a, d). Comparing HG, MG, and
cytokines, induction of proinflammatory genes and oxida-
tive stress in both cell types was highest after a 5-day
treatment with MG, followed by HG and cytokines
(Fig. 6a). RPTEC had highest expression of negative regu-
lators and lowest expression of TLR signaling molecules in
response to MG. However, no significant change was ob-
served in MG-treated NHMC. To determine if the immune
response of RPTEC was impaired in conditions that simu-
lated the metabolic milieu of diabetes, we compared protein
and mRNA expression profiles of RPTEC challenged with
LPS alone (Fig. 6b, c) or a combination of LPS, lipoteichoic
acid, and poly(I:C) (Fig. 6d, e), before and after a 5-day
incubation with HG, MG, and cytokines. In the same exper-
iment, we also investigated the effects of DPI, an antioxi-
dant that targets NADPH oxidase, alone or in combination
with a PKC inhibitor, Gö6983, on the immune response of
RPTEC. RPTEC exposed to conditions mimicking the dia-
betic metabolic milieu showed a delayed response to LPS
stimulation. Activation of TLR leading to NFκB and p38
MAPK activation was evident only 12 h after LPS stimula-
tion (Fig. 6c) compared with control-unexposed RPTEC
that responded to LPS stimulation within 2 h (Fig. 6b). This
delayed response of RPTEC in a diabetic milieu was
associated with expression of negative regulators
(Fig. 6c) and less robust expression of molecules associ-
ated with antimicrobial response (e.g., PIGR, LEAP2, LTF,
C2, C3, C4A, C5, TAP1, TAP2, and TAPBP) when chal-
lenged with microbial analogs. This was associated with
upregulation of multiple immunomodulatory cytokines,
negative regulators of inflammation, increased ROS gen-
eration, and evidence of impaired intrinsic antioxidant
capacity (Fig. 6d, e). The combined presence of Gö6983
and DPI (Fig. 6b, d, e), but not either agent alone
(Fig. 6b), mitigated the proinflammatory response, reduced
the expression of negative regulators, and restored the
prompt immune response of RPTEC challenged with mi-
crobial stimulants. Collectively, these in vitro results point
to inappropriately heightened counter-regulatory responses
to inflammation as a cause of impaired renal epithelial
immunity in diabetes and demonstrate reversal by pharma-
cological interventions directed at PKC activation and
ROS generation.
Discussion
Our results showed that kidneys of diabetic subjects overex-
pressed inflammatory markers, and had dysregulated signal-
ing pathways involving GPCR, PKC-β, MAPKs (p38MAPK
and JNK), Akt, TLRs, and NFκB. Our data additionally
revealed Nox4-induced ROS generation, hyperglycemia-
Fig. 5 T and B lymphocyte
infiltrations of diabetic kidneys.
Immunohistochemical staining
for B (a, c) and T lymphocytes
(b, d) of two diabetic kidneys
(top case 05-PB20861 and bot-
tom case 06-PB627) with evi-
dence of bacterial and HCMV
DNA. Primary antibodies were
monoclonal anti-CD20 (B lym-
phocytes; Dako M0755, clone
L26; 1:200 dilution) and poly-
clonal anti-CD3 (T lympho-
cytes; Dako A0452; dilution
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Fig. 6 Renal tubular epithelial cells, but not mesangial cells, modulate
overt inflammation via negative feedback mechanisms that impair
immunity. a Human renal primary tubular epithelial cells (RPTEC)
and mesangial cells (NHMC; Lonza) were cultured with diabetes-
relevant concentrations of cytokines (TNF-α, 50 pg/ml; IL-6, 20 pg/
ml; and IL-1β, 20 pg/ml), high glucose (HG; 20 mM) or methylglyoxal
(MG; 10 μM) for 3 h or 5 days (120 h). Protein lysates from each
condition (n04) were prepared for western blot analysis using the
indicated antibodies (n≥3 for each antibody). b RPTEC were first
exposed to a combination of cytokines, high glucose, and methyl-
glyoxal at concentrations stated in (a) for 5 days. The cells were further
cultured in fresh medium in the presence of either diphenyleneiodo-
nium chloride (DPI; 10 μM) or combined with Gö6983 (10 nM) for
1 day before challenge with lipopolysaccharide (LPS; 1 μg/ml) for 2 h.
Protein lysates (n04 for each condition) were analyzed by western
blotting (≥3 immunoblots for each antibody). c RPTEC cultured in the
combined presence of cytokines, HG and MG at the aforementioned
concentrations for 5 days were challenged with a higher dose of LPS
(10 μg/ml) for the indicated time points (n04 for each time point).
Minus 1 h denotes cells that were not exposed to LPS but were lysed
for protein isolation one hour before similarly cultured cells were
challenged with LPS. Protein lysates from each condition were pre-
pared for western blotting as described (Figs. 2 and 3 legends). d
RPTEC and NHMC were treated as follows before harvesting for
protein and total RNA isolations (n04 for each condition). I Untreated
control cells; II incubated with cytokines (TNF-α, 50 pg/ml; IL-6,
20 pg/ml; and IL-1β, 20 pg/ml), HG (20 mM), and MG (10 μM) for
5 days; III incubated with MG (10 μM) only for 5 days; IV challenged
with LPS (10 μg/ml), lipoteichoic acid (LTA; 10 μg/ml), and poly(I:C)
(10 μg/ml) for 2 h; V treated as in (II) before returning to normal
culture medium for 1 day and subsequently challenged with microbial
stimulants as in (IV); VI cultured as in (II) before treatment with DPI
(10 μM) and Gö6983 (10 nM) for 1 day in fresh culture medium; VII
cultured as in (VI) before challenge as in (IV). Protein lysates were
assayed using quantitative protein arrays. e Results of qPCR array
plotted as fold change (RPTEC of each condition cf. untreated
RPTEC). Genes with similar functions or involvement in the same
biological process were grouped. A Diabetes related, B inflammatory
pathways, C antioxidant system, D negative immune regulators, E
interleukin and cytokine receptors, F TLR signaling, and G antimicro-
bial molecules and adaptive immunity. Roman numerals (I–V) indicate
the type of treatment. I RPTEC incubated with cytokines (TNF-α,
50 pg/ml; IL-6, 20 pg/ml; and IL-1β, 20 pg/ml), HG (20 mM), and
MG (10 μM) for 5 days; II RPTEC challenged with LPS (10 μg/ml),
LTA (10 μg/ml) and poly I/C (10 μg/ml) for 2 h; III RPTEC treated as
in (I), returned to normal culture medium for 1 day and then challenged
with microbial analogs as in (II); IV RPTEC cultured as in (I) before
combined treatment with DPI (10 μM) and Gö6983 (10 nM) for 1 day
in fresh culture medium; V RPTEC cultured as in (IV) before being
challenged as in (II). The qPCR array experiment for each of the
conditions was performed twice
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induced mitochondrial dysfunction leading to reduced antiox-
idant capacity, NFAT5 overexpression, and glucose-induced
upregulation of EGR1. EGR1 heterodimerizes with NFAT5 to
induce proinflammatory cytokine gene expression [28].
Our results help to explain the association of impaired
immunity with frequent infections by showing that inappro-
priate induction of immunomodulatory molecules and nega-
tive regulators of inflammatory pathways accompany
heightened inflammatory responses in diabetic kidneys. This
suggests that clinically subtle immunocompromise can result
from conserved regulatory responses evolved for combating
biological stressors, e.g., hyperglycemia and chronic inflam-
mation. Indeed, immune responses and metabolic regulation
are interdependent in maintaining homeostatic equilibrium
[25]. Alternative mechanisms of impaired immunity in diabe-
tes are known. Hyperglycemia induces overexpression of
endogenous TLR4 ligands, fibronectin, and biglycan. Chronic
TLR4 activation leads to hypo-responsiveness to PAMPs [29,
30]. This suggests an explanation for our results showing
downregulation of surface TLRs (e.g., TLR2 and TLR4) in
diabetic kidneys. In contrast, the expression of cytosolic,
endosome-bound TLRs, e.g., TLR3 and TLR7, and an intra-
cellular RNA helicase, RIG-1, were induced in infected dia-
betic kidneys because they recognize intracellular microbial
patterns [31].
Recognizing the inherent heterogeneity of whole tissue
analysis, we complemented whole kidney studies with in
vitro experiments on subtypes of primary human renal cells.
Our results confirmed the active role of renal epithelial cells
as key players in renal tissue immunity, in contrast to renal
mesangial cells having a more passive function. Although
mesangial cells are metabolically vulnerable because they
Fig. 7 Proposed model showing molecular mechanisms of dysregu-
lated immune pathways in diabetic renal tissues. Hyperglycemia alters
four molecular processes implicated in the pathogenesis of diabetes
complications: (1) polyol pathway, (2) increased expression of the
receptor for advanced glycation end-product, (3) hexosamine pathway,
and (4) protein kinase C (PKC) signaling. This results in chronic
inflammation, accumulation of extracellular matrix proteins, tissue
remodeling, mitochondrial dysfunction, and oxidative stress. Chronic
activation of the key switches of proinflammatory responses, e.g.,
PKC-β, NF-κB, MAPKs, AKT, G protein-coupled receptors (GPCRs),
and Toll-like receptors (TLRs) are induced. Oxidative stress from
increased generation of reactive oxygen species (ROS), impaired mi-
tochondrial function and diminished antioxidant capacity further exac-
erbates the proinflammatory state, especially when ROS and PKC-β
are mutually activating and oxidative stress activates NF-κB. To com-
bat and protect resident cells and tissue from unresolved inflammation,
anti-inflammatory mechanisms involving negative regulators of proin-
flammatory molecules and signaling pathways (yellow letters), immu-
nomodulatory molecules (e.g., IL4, TSLP, and CXCL14), and decoy
receptors (e.g., IL1-R1, IL6-R1, and IL13RA2) are chronically acti-
vated. These inherent protective mechanisms however compromise
antimicrobial defense by interfering with TLR and NF-κB signaling
that in turn reduce expression of key players of innate and adaptive
immunity (e.g., circulating antimicrobial peptides and complement
factors, and proteins with important roles in antigen presentation).
Impaired immunity predisposes to infections that activate cytoplasmic
pathogen-associated molecular pattern receptors which recognize in-
ternalized bacterial and viral molecules. Information was derived from
Ingenuity Pathways Knowledge Base and published literature. Red
letters denote upregulation; green letters, downregulation; black let-
ters, mechanisms/modulators not analyzed in this study
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cannot restrain intracellular glucose transport and hence
tend to overexpress markers of inflammation [32], our data
show that their role in tissue immunity is minimal. We
propose that renal epithelial cells respond to heightened
inflammation and oxidative stress by upregulating immuno-
modulatory molecules that may influence immune cells of
the microenvironment to favor TH2 responses. Concurrent-
ly, epithelial cells protect themselves from excessive inflam-
mation by expressing a myriad of negative regulators to
inhibit inflammatory signaling, particularly the TLR path-
way [33]. While it may be effective in helping to extinguish
inflammation, this strategy is not without cost to the im-
mune system and the diabetic host, as our findings of cryptic
HCMV and/or bacterial infections show. As about one third
of diabetic patients develop nephropathy and end-stage re-
nal failure, it is possible that impaired immunity and cryptic
infections are contributory factors.
Our in vitro experiments confirmed the role of inflam-
mation and oxidative stress as the main instigators of im-
paired immunity in diabetes as combined pharmacological
intervention with a PKC inhibitor and an antioxidant target-
ing the ROS generator, NADPH oxidase, but not either
agent alone, reversed the molecular dysregulation initiated
by common molecular assaults of diabetes and restored a
prompt immune response of renal epithelial cells. Our data
further confirm and highlight the role of MG in impairing
immune functions in diabetes [34]. We show MG to be
potent in triggering overexpression of inflammatory mole-
cules and ROS in renal epithelial and mesangial cells, with
subsequent impairment of TLR signaling in epithelial cells.
In conclusion, our data suggest an integrated model for
diabetes-impaired immunity (Fig. 7). Hyperglycemia indu-
ces changes in multiple intrarenal pathways involving
mechanisms implicated in tissue damage [32]. These result
in mitochondrial dysfunction and oxidative stress, a net
effect of diminished antioxidant capability and accumula-
tion of intracellular ROS. Other crucial effects are accumu-
lation of extracellular matrix proteins and proinflammatory
responses involving activation of NF-κB, MAPKs, and Akt.
Activation of GPCR signaling by ligands such as cytokines,
chemokines, lipid and growth factors, and oxidative stress
create a vicious cycle of chronic inflammation. In turn, renal
epithelial cells mount protective mechanisms to combat
these stressors by stimulating the capacity to restore immune
homeostasis through inducing TH2 and anti-inflammatory
responses, and overexpressing negative regulators that in-
tercept proinflammatory responses, especially those directed
at TLR signaling and NF-κB. These may interfere with
selective transcription of genes regulated by NFκB, other
inflammatory transcription factors and the physiological
synergy among them [35]. Thus, the expression of target
genes of innate and adaptive immunity could be compro-
mised, resulting in increased risk of infections. Internalized
bacterial and viral molecules during the course of renal
infection may activate cytosolic PAMP receptors, triggering
yet another wave of inflammatory response.
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